Overview
- HRSA guidance requires private insurers to pay 100% for FDA‑authorized HPV self‑sampling for people aged 30–65 at average risk starting January 1, 2027.
- Eligible users can self‑collect at home or in clinics with approved kits, then mail samples to certified laboratories for analysis and results returned in days.
- Teal Health’s Teal Wand is currently the only FDA‑authorized at‑home self‑sampling device available in the United States.
- UNAM researchers are clinically validating with Cofepris a portable biosensor that targets 10 high‑risk HPV genotypes and delivers color‑based results in about 30 minutes from a self‑collected swab.
- While validation proceeds, UNAM provides ISO 9001‑certified PCR HPV testing at LaNSBioDyT and plans outreach to underserved areas, noting persistent screening gaps in Mexico.